What this means
This is a trial that is still recruiting people. It will check frailty with geriatric tools and biological age using DNA methylation tests. No results have been posted, so it does not yet show what the tests mean for care.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 18 and over
- Where
- 17 sites
The science
- Registered title
- Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy
- Trial ID
- NCT06130787 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Leukemia,Myeloid, Chronic
- What is tested
- Blood and bone marrow sample
- Sponsor
- University Hospital, Clermont-Ferrand
- Ages
- 18 Years to no maximum
- Dates
- First posted Nov 14, 2023 · updated Sep 27, 2024
Registry summary
French prospective multicenter, open-label study involving newly diagnosed CML patients. Two assessments will be performed during the follow-up of these patients: individual frailty using geriatric tools and individual biological aging determined by DNA methylation analysis.
Sites (17)
- CHU Annecy-Genevois, Annecy, France
- Institut Bergonié, Bordeaux, France
- CHU Caen, Caen, France
- CHU de Clermont-Ferrand, Clermont-Ferrand, France
- CHU Créteil, Créteil, France
- CHU Grenoble Alpes, Grenoble, France
- Centre Hospitalier Emile Roux, Le Puy-en-Velay, France
- CHRU Lille, Lille, France
- CHU Limoges, Limoges, France
- Centre Léon Bérard, Lyon, France
- Institut Paoli-Calmettes, Marseille, France
- CHU Nancy, Nancy, France
- Groupe Hospitalier Paris Saclay - Site de Bicêtre, Paris, France
- CHU Rennes, Rennes, France
- CHU Saint-Etienne, Saint-Etienne, France
And 2 more on the listing.